Pfizer (PFE) Stock

Major vaccine companies such as Eli Lilly, Pfizer, and AstraZeneca may not be in the news as much since the height of the COVID-19 pandemic, but there are signs that interest in them could rise again. With the possibility of a second Trump administration, investors are paying attention to the nomination of Robert F. Kennedy Jr., who is known for his critical views on vaccines.

Pfizer (PFE 0.23%) has been struggling recently, despite reporting some good earnings. Investors are worried about significant challenges that could decrease its $145 billion value in the future.

A selection of strong dividend-growth stocks that are close to their 52-week lows is analyzed using past and expected fair values. Pfizer's financial situation raises some worries due to its high dividend payout ratios and negative debt-to-equity ratios, but forecasts indicate a chance for improvement. Even with political risks and worries from activist investors, PFE's attractive initial dividend yield, good ratings, and encouraging product pipeline could mean it is undervalued.

While no one can foresee what will happen in the future, it's easy to picture a rise in pharmaceutical sales. In 2022, spending on prescription drugs in the U.S. grew by over 8%, totaling $406 billion.

Pfizer's shares seem to be undervalued, offering a high dividend yield of 6.8%, which could make it a good long-term investment even with low growth predictions. The company had impressive Q3 results, showing a 31.2% year-over-year revenue increase, mainly due to products like Paxlovid and Comirnaty. Although the valuation multiples are high, a discounted cash flow analysis indicates that Pfizer's true value is $37.56 with a 3% growth rate, suggesting it may be undervalued.

After receiving approval from the European Commission, PFE's Hympavzi is now the first hemophilia treatment in the European Union that can be given using a pre-filled auto-injector pen.

Investors looking at Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Novo Nordisk (NVO). However, which of these two companies currently provides better value for investors?

The pharmaceutical company has been looking for a new chief scientific officer since July, following Mikael Dolsten's departure after 15 years with the firm.

According to a report from the WSJ on Wednesday, Pfizer has appointed Chris Boshoff, a long-time employee who has been in charge of the company's cancer research and marketing for over a year, as its new head of research and development.